hVIVO has announced positive result for the primary endpoint, following completion of analysis of samples by NIAID and additional results from the Phase IIb viral challenge study of FLU-v, (Study 004, NCT03180801).
NeuroBo Pharmaceuticals has announced its plans to initiate a phase III trial to evaluate the efficacy of its lead drug, NB-01, in diabetic neuropathic pain in early second quarter of this year.
Pfizer has started a phase 2b/3 clinical trial of PF-06651600, an oral JAK3 inhibitor to treat patients with moderate to severe alopecia areata.
Deciphera Pharmaceuticals has initiated an open-label, multicenter, phase 1b/2 study of rebastinib, the company’s investigational small molecule switch control inhibitor of TIE2 kinase, in combination with carboplatin in patients with advanced or metastatic solid tumors.
Spectrum Pharmaceuticals has announced full enrollment of cohort 1 (N=87) for previously treated non-small cell lung cancer (NSCLC) patients with EGFR exon 20 insertion mutations with sites across the US, Europe, and Canada.
Astellas Pharma and Pfizer reported that the phase 3 ARCHES trial evaluating XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) in men with metastatic hormone-sensitive prostate cancer (mHSPC) met its primary endpoint, improving radiographic progression-free survival (rPFS) significantly in comparison to ADT alone.
Lynparza (olaparib), a poly ADP-ribose polymerase (PARP) inhibitor, co-developed by AstraZeneca and Merck (known as MSD outside the US and Canada), has succeeded in a phase 3 trial held in patients with relapsed BRCA-mutated (BRCAm) advanced ovarian cancer by meeting the primary endpoint.
Teva Pharmaceutical Industries said that the phase IIIb FOCUS study that evaluated the efficacy and safety of fremanezumab for the preventive treatment of migraine in adult patients has yielded positive results.
Vedanta Biosciences, which was founded by PureTech Health, has commenced a phase 2 study of its rationally-defined bacterial consortium product candidate, VE303, for recurrent Clostridium difficile infection (rCDI).
Janssen Pharmaceutical said that Tremfya (guselkumab) was found to be superior to Cosentyx (secukinumab) for the primary endpoint assessed at week 48 of a phase 3 trial in adults with moderate to severe plaque psoriasis.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.